Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Efficacy of TAGRISSO® (osimertinib) in Resectable EGFRm NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib Shows No OS Benefit Versus Chemotherapy in EGFR T790M-Mutant Advanced NSCLC Study
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - ScienceDirect
AstraZeneca's TAGRISSO® (osimertinib) shows potential as a new standard of care in 1st-line EGFR-mutated non-small cell lung cancer at ESMO 2017 Congress
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Osimertinib Continues to Impress With Response and Disease Control Rates in NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | SpringerLink
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Scientific Reports
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
